<DOC>
	<DOCNO>NCT00494091</DOCNO>
	<brief_summary>This study evaluate safety , efficacy pharmacokinetics temsirolimus Asian patient advance renal cell carcinoma . The trial conduct Japan , Korea , China .</brief_summary>
	<brief_title>Study Evaluating The Safety , Efficacy &amp; Pharmacokinetics Of Temsirolimus ( CCI-779 ) In Subjects With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Subjects histologically confirm , advance ( stage IV recurrent disease ) RCC . The American Joint Committee Cancer ( AJCC ) stag classification criterion use . ECOG performance status 01 . At least one measurable lesion per RECIST . Age great equal 20 year . Japanese , Chinese , Korean ethnicity . CNS metastases screen history CNS metastases . Prior target , chemotherapeutic , cytokinebased , investigational agent treatment RCC within 4 week first dose test article . Subjects must document objective progressive disease prior systemic RCC treatment recover grade 1 low toxicity effect prior systemic therapy RCC . In past 5 year , prior malignancy ( except basal cell carcinoma , squamous cell carcinoma skin , cervical carcinoma situ ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>